Two papers published online in Nature Biotechnology report an epigenetic editing platform that enables simultaneous multi‑gene reprogramming of primary human T cells, and an integrated epigenetic/genetic programming approach to create enhanced cell therapies. The work comes from the Arc Institute, Gladstone, UCSF and collaborators and demonstrates multiplexed editing that improves T cell function while minimizing genomic disruption. Authors describe methods that combine CRISPR tools with targeted epigenetic modulation to tune expression programs across multiple loci, producing T cells with enhanced persistence and anti‑tumor phenotypes. The studies include proof‑of‑concept data in preclinical models and detail manufacturing‑compatible workflows. If validated in clinical studies, these methods could shorten the path to multi‑antigen CAR‑T products and complex cellular programs while addressing safety concerns tied to multiplexed DNA edits.